Characteristic | N (%) |
Age |
|
Median | 65 |
Range | 41 - 86 |
<75 | 60 (83.3) |
Male | 47 (65.3) |
Race |
|
White | 37 (51.4) |
Black | 30 (41.7) |
Other | 3 (4.2) |
ECOG PSa |
|
0 | 26 (36.1) |
1 | 36 (50) |
2 | 10 (13.9) |
3 | 0 (0) |
Smoking historyb |
|
Light/never | 18 (25) |
Heavy | 51 (70.8) |
Histology |
|
Non-squamous | 57 (79.2) |
Squamous | 15 (20.8) |
Targetable driver mutationc |
|
EGFR | 9 (12.5) |
ALK | 0 |
ROS-1 | 0 |
Site of metastases at initiation of therapy |
|
Bone | 20 (27.8) |
Liver | 13 (18.1) |
Brain | 11 (15.3) |
Line of therapy |
|
2 | 36 (50) |
3 | 20 (27.8) |
4+ | 9 (12.5) |
Therapy |
|
Nivolumab | 54 (75) |
Pembrolizumab | 18 (25) |
dNLR |
|
<3 | 55 (76.4) |
≥3 | 17 (23.6) |